CRMD News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

CR

Mkt Cap

$567.0M

Volume

947.38K

Next Earnings

November 11th

Loading chart

CR

CRMDCorMedix Inc.

CRMD

Pay with—

Available Balance0.00

CR

Mkt Cap

$581.5M

Volume

947.38K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?In a comparison of two medical-biomedical stocks, CorMedix (CRMD) emerges as the superior value option over Prothena (PRTA). CRMD holds a Zacks Rank of #2 (Buy) with a Value grade of A, featuring a forward P/E of 13.48 and PEG ratio of 1.35. PRTA, ranked #3 (Hold) with a Value grade of F, has a forward P/E of 66.51 and PEG ratio of 1.99, indicating it is significantly more expensive relative to its growth prospects.Zacks Investment Research · Oct 8, 2026

CorMedix Builds a Real Revenue Story as DefenCath Adoption AcceleratesCorMedix is experiencing strong commercial momentum with its DefenCath catheter lock solution, which has shown a 72% reduction in catheter-related bloodstream infections in real-world evidence studies. The company reported Q3 2025 net revenue of $104.3 million and raised full-year guidance to $390-410 million. DefenCath adoption is outpacing expectations, and the Melinta Therapeutics acquisition adds diversification. Analysts are optimistic with nearly-unanimous Buy ratings and see 48% upside potential, though risks include pricing pressure and pipeline concentration.Investing.com · Dec 24, 2025

American Kidney Fund Hosts Third Patient Access Initiative Summit to Address Barriers to Kidney Care and Propose Innovative SolutionsThe American Kidney Fund hosted its third annual Patient Access Initiative Summit focusing on innovative kidney care technologies, AI applications, and addressing barriers to kidney disease prevention and treatment.GlobeNewswire Inc. · Nov 21, 2025

Strong Earnings and Biotech Resilience Define the Midweek MomentumSeveral biotech companies reported significant developments, including Kraig Labs' breakthrough in spider silk production, Salarius Pharmaceuticals' public offering, Humacyte's Q3 progress, and CorMedix's record quarterly earnings.GlobeNewswire Inc. · Nov 12, 2025

CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYOCorMedix completed enrollment in a Phase III clinical trial for REZZAYO, a drug aimed at preventing fungal infections in patients undergoing blood and marrow transplantation. Topline results are expected in Q2 2026, with potential FDA approval for prophylaxis treatment.Benzinga · Sep 29, 2025

CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership TeamCorMedix has successfully acquired Melinta Therapeutics for $300 million, expanding its commercial product portfolio with seven innovative drug products and raising financial guidance to $325-$350 million in pro forma 2025 revenues.Benzinga · Sep 2, 2025

Closed System Transfer Device Market Size Poised to Hit USD 4,753.71 million by 2034, Driven by a 14.1% CAGR | PMRThe global closed system transfer device market is projected to grow from $1.1 billion in 2024 to $4.8 billion by 2034, driven by advancements in technology and increasing cancer cases worldwide.GlobeNewswire Inc. · Dec 10, 2024

Here's Why CorMedix Is a Great 'Buy the Bottom' Stock NowCorMedix (CRMD) stock has been struggling, but a hammer chart pattern and strong earnings estimate revisions suggest a potential trend reversal. The article highlights the technical and fundamental factors that make CRMD a good 'buy the bottom' stock.Benzinga · Sep 9, 2024

CorMedix Inc. Announces New Commercial AgreementCorMedix Inc. has entered into a multi-year commercial supply contract with a global healthcare company for the supply of its approved product DefenCath, which is used to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis.GlobeNewswire Inc. · Sep 9, 2024

CorMedix Inc. Announces CMS Grants Pass-Through Status to DefencathBERKELEY HEIGHTS, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that the Center for Medicare & Medicaid Services (CMS) has determined that DefenCath® qualifies for pass-through status under the hospital Out-Patient Prospective Payment System (OPPS). Pass-through status provides for separate payment under Medicare Part B for the utilization of DefenCath in the out-patient ambulatory setting for a period of at least two years, and up to a maximum of three years.GlobeNewswire Inc. · Jun 6, 2024

to start trading

CR

CRMDCorMedix Inc.

CRMD

Pay with—

Available Balance0.00

Your PositionYou don't own any CRMD yet.

Related Tickers

Earnings